메뉴 바로가기 본문 바로가기

TEST ITEMS

THE GENERATION DIAGNOSTIC SYSTEM

Progesterone

Progesterone also known as P4 (pregn-4-ene-3,20-dione) is a C-21 steroid hormone involved in the female menstrual cycle, pregnancy (supports gestation) and embryogenesis of humans and other species.[2]
Progesterone is essential for the regulation of normal female reproductive functions. The major physiological actions of progesterone are: a) in the uterus and ovary: induction of ovulation, facilitation of implantation, and maintenance of early pregnancy; b) in the mammary gland: lobular-alveolar development in preparation for milk secretion[3,4]; c) in the brain: neurobehavioral expression associated with sexual responsiveness[5] and d) in the bone: prevention of bone loss[6].
During the follicular phase of the cycle, progesterone levels remain low.[7-9] Following the LH surge and ovulation, luteal cells in the ruptured follicle produce progesterone in response to LH. During this, the luteal phase, progesterone rises rapidly to a maximum of 10-20 ng/mL at day following ovulation. During the luteal phase, progesterone transforms the estrogen-primed endometrium from a proliferative to a secretory state.[8] If pregnancy does not occur, progesterone levels decrease during the last four days of the cycle due to the regression of the corpus luteum.[7,8-13] If conception occurs, the levels of progesterone are maintained at mid-luteal levels by the corpus luteum until about week six. At that time the placenta becomes the main source of progesterone and levels rise from approximately 10-50 ng/mL in the first trimester to approximately 50-280 ng/mL in the third trimester.[7,14,15]

References

  • 1. Potential use of single measurement of serum progesterone in detecting early pregnancy failure Hanita O MD, MPATH, Hanisah AH MD, MPATH
  • 2. Metabocard for Hydroxyprogesterone. Human Metabolome Database. Retrieved 31 July 2013.
  • 3. Progestin regulation of cellular proliferation. Clark CL and Sutherland RL. Endocrine Review 1990;11: 266-301.
  • 4. Physiological Action of Progesterone in Target Tissues. Graham JD and Clarke CL. Endocrine Reviews 1997;18: 502-519.
  • 5. Progesterone, progestagens and the central nervous system. Hum Reprod Genazzani AR, Stomati M, Morittu A, Bernardi F, Monteleone P, Casarosa E, Gallo R, Salvestroni C and Luisi M. 2000; 15: 14-27.
  • 6. Sex steroids and bone: current perspectives. Hum reprod update. Balasch J. 2003; 9: 207-22.
  • 7. Simultaneous Radioimmunoassay of Plasma FSH, LH, Progesterone, 17-Hydroxyprogesterone, and Estradiol-17 beta During the Menstrual Cycle. Abraham GE, Odell WD, Swerdloff RS, Hopper K. J Clin Endocrinol Metab, 1972; 34:2, 312–318.
  • 8. Studies on the Pattern of Circulating Steroids in the Normal Menstrual Cycle. Aedo AR, Nunez M, Landgren BM, Cekan SZ, Diczfalusy E. Circadian Variation in Theperi-Ovulatory Period. Acta Endocrinol (Copenh), 1977; 84:2, 320-332
  • 9. Hormonal Profile of the Cycle in 68 Normally Menstruating Women. Landgren BM, Unden AL, and Diczfalusy E. Acta Endocrinol (Copenh), 1980; 94:1, 89-98.
  • 10. Normal Ovarian Function. Erickson GG. Clin Obstet Gynecol, 1978; vol. 21 No.1, 31-53.
  • 11. Physiological Profiles of Episodic Progesterone Release During the Midluteal Phase of the Human Menstrual Cycle: Analysis of Circadian and Ultradian Rhythms, Discrete Pulse Properties, and Correlations with Simultaneous Luteinizing Hormone Release. Veldhuis JD, Christiansen E, Evans WS, Kolp LA, Rogol AD, Johnson ML. J Clin Endocrinol Metab, 1988; 66:2, 414-421.
  • 12. Neuroendocrine Regulation of the Corpus Luteum in the Human. Evidence for Pulsatile Progesterone Secretion. Filicori M, Butler JP, Crowley WF Jr., J Clin Invest, 1984; 73:6, 1638-1647.
  • 13. The Pattern of Luteal Phase Plasma Progesterone and Estradiol in Fertile Cycles. Laufer N, Navot D, Schenker JG. Am J Obstet Gynecol, 1982; 143:7, 808-813.
  • 14. Method for Monitoring Plasma Progesterone Concentrations in Pregnancy. Winkel P, Gaede P, Lyngbye J Clin Chem 1976; 22:4,422-428.
  • 15. The Applications of Steroid Hormone Radioimmunoassays to Clinical Obstetrics. Buster JE, Abraham GE. Obstet Gynecol, 1975; 46:4, 489-499

ichroma™

Compatible Device ichroma™ I/II
Detection Range 1.4~40 ng/mL 4.45~127.2 nmol/mL
Sample Type Serum, Plasma
CV <10%
Comparability 0.985
Reaction Time 15Min

Product News